Medical - Healthcare Plans
Compare Stocks
5 / 10Stock Comparison
HUM vs UNH vs CVS vs ELV vs CNC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
HUM vs UNH vs CVS vs ELV vs CNC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $28.76B | $330.28B | $102.56B | $80.15B | $26.15B |
| Revenue (TTM) | $137.20B | $449.71B | $402.07B | $200.41B | $198.10B |
| Net Income (TTM) | $1.13B | $12.04B | $1.77B | $5.24B | $-6.44B |
| Gross Margin | 14.0% | 18.8% | 13.8% | 23.2% | 14.9% |
| Operating Margin | 1.0% | 4.2% | 1.2% | 3.8% | -3.7% |
| Forward P/E | 26.8x | 19.9x | 11.3x | 13.8x | 15.7x |
| Total Debt | $12.94B | $78.39B | $93.59B | $33.23B | $18.78B |
| Cash & Equiv. | $4.20B | $24.36B | $8.51B | $9.49B | $17.89B |
HUM vs UNH vs CVS vs ELV vs CNC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Humana Inc. (HUM) | 100 | 58.3 | -41.7% |
| UnitedHealth Group … (UNH) | 100 | 119.4 | +19.4% |
| CVS Health Corporat… (CVS) | 100 | 123.1 | +23.1% |
| Elevance Health Inc. (ELV) | 100 | 125.5 | +25.5% |
| Centene Corporation (CNC) | 100 | 79.9 | -20.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HUM vs UNH vs CVS vs ELV vs CNC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, HUM doesn't own a clear edge in any measured category.
UNH is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 217.0% 10Y total return vs ELV's 202.3%
- Combined ratio 1.0 vs CNC's 1.0 (lower = better underwriting)
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.3%
- Beta 0.05, yield 3.3%, current ratio 0.84x
- Lower P/E (11.3x vs 13.8x)
- Beta 0.05 vs UNH's 0.59
ELV ranks third and is worth considering specifically for growth exposure.
- Rev growth 12.6%, EPS growth -2.2%, 3Y rev CAGR 8.3%
- 4.3% ROA vs CNC's -7.9%, ROIC 9.1% vs -21.6%
CNC is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.39, Low D/E 93.6%, current ratio 1.68x
- 19.4% revenue growth vs CVS's 7.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.4% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (11.3x vs 13.8x) | |
| Quality / Margins | Combined ratio 1.0 vs CNC's 1.0 (lower = better underwriting) | |
| Stability / Safety | Beta 0.05 vs UNH's 0.59 | |
| Dividends | 3.3% yield, vs UNH's 2.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +24.2% vs CNC's -11.4% | |
| Efficiency (ROA) | 4.3% ROA vs CNC's -7.9%, ROIC 9.1% vs -21.6% |
HUM vs UNH vs CVS vs ELV vs CNC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HUM vs UNH vs CVS vs ELV vs CNC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CVS leads in 2 of 6 categories
UNH leads 1 • CNC leads 1 • ELV leads 1 • HUM leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 3.3x HUM's $137.2B. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to CNC's -3.3%. On growth, HUM holds the edge at +23.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $137.2B | $449.7B | $402.1B | $200.4B | $198.1B |
| EBITDAEarnings before interest/tax | $2.2B | $23.2B | $9.3B | $8.9B | -$5.9B |
| Net IncomeAfter-tax profit | $1.1B | $12.0B | $1.8B | $5.2B | -$6.4B |
| Free Cash FlowCash after capex | $1.3B | $19.7B | $7.8B | $6.5B | $6.3B |
| Gross MarginGross profit ÷ Revenue | +14.0% | +18.8% | +13.8% | +23.2% | +14.9% |
| Operating MarginEBIT ÷ Revenue | +1.0% | +4.2% | +1.2% | +3.8% | -3.7% |
| Net MarginNet income ÷ Revenue | +0.8% | +2.7% | +0.4% | +2.6% | -3.3% |
| FCF MarginFCF ÷ Revenue | +0.9% | +4.4% | +1.9% | +3.2% | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +23.5% | +2.0% | +8.2% | +2.6% | +7.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.6% | +0.7% | +76.9% | -16.8% | +18.3% |
Valuation Metrics
CNC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 14.7x trailing earnings, ELV trades at a 75% valuation discount to CVS's 58.1x P/E. On an enterprise value basis, ELV's 10.8x EV/EBITDA is more attractive than UNH's 16.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $28.8B | $330.3B | $102.6B | $80.1B | $26.2B |
| Enterprise ValueMkt cap + debt − cash | $37.5B | $384.3B | $187.6B | $103.9B | $27.0B |
| Trailing P/EPrice ÷ TTM EPS | 24.34x | 27.50x | 58.05x | 14.69x | -3.89x |
| Forward P/EPrice ÷ next-FY EPS est. | 26.82x | 19.87x | 11.27x | 13.79x | 15.70x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.12x | — |
| EV / EBITDAEnterprise value multiple | 16.47x | 16.48x | 12.52x | 10.76x | — |
| Price / SalesMarket cap ÷ Revenue | 0.22x | 0.74x | 0.26x | 0.40x | 0.13x |
| Price / BookPrice ÷ Book value/share | 1.63x | 3.26x | 1.36x | 1.86x | 1.30x |
| Price / FCFMarket cap ÷ FCF | 76.69x | 20.55x | 13.14x | 25.25x | 6.05x |
Profitability & Efficiency
ELV leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ELV delivers a 11.9% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-29 for CNC. HUM carries lower financial leverage with a 0.73x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs CVS's 5/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.2% | +11.5% | +2.3% | +11.9% | -28.6% |
| ROA (TTM)Return on assets | +2.2% | +3.9% | +0.7% | +4.3% | -7.9% |
| ROICReturn on invested capital | +4.1% | +9.2% | +5.0% | +9.1% | -21.6% |
| ROCEReturn on capital employed | +4.0% | +9.7% | +6.1% | +8.2% | -14.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.73x | 0.77x | 1.24x | 0.75x | 0.94x |
| Net DebtTotal debt minus cash | $8.7B | $54.0B | $85.1B | $23.7B | $889M |
| Cash & Equiv.Liquid assets | $4.2B | $24.4B | $8.5B | $9.5B | $17.9B |
| Total DebtShort + long-term debt | $12.9B | $78.4B | $93.6B | $33.2B | $18.8B |
| Interest CoverageEBIT ÷ Interest expense | 3.08x | 4.71x | 1.68x | 5.39x | -9.03x |
Total Returns (Dividends Reinvested)
CVS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,195 today (with dividends reinvested), compared to $5,570 for HUM. Over the past 12 months, CVS leads with a +24.2% total return vs CNC's -11.4%. The 3-year compound annual growth rate (CAGR) favors CVS at 7.8% vs HUM's -22.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.1% | +8.8% | +2.4% | +4.7% | +26.8% |
| 1-Year ReturnPast 12 months | -5.3% | -7.9% | +24.2% | -9.7% | -11.4% |
| 3-Year ReturnCumulative with dividends | -53.2% | -21.4% | +25.3% | -16.3% | -22.6% |
| 5-Year ReturnCumulative with dividends | -44.3% | -2.8% | +11.9% | +2.4% | -18.9% |
| 10-Year ReturnCumulative with dividends | +52.9% | +217.0% | -2.2% | +202.3% | +74.6% |
| CAGR (3Y)Annualised 3-year return | -22.4% | -7.7% | +7.8% | -5.8% | -8.2% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than UNH's 0.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 94.8% from its 52-week high vs HUM's 76.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.56x | 0.59x | 0.05x | 0.46x | 0.39x |
| 52-Week HighHighest price in past year | $315.35 | $409.70 | $85.15 | $424.24 | $64.15 |
| 52-Week LowLowest price in past year | $163.11 | $234.60 | $58.35 | $273.71 | $25.08 |
| % of 52W HighCurrent price vs 52-week peak | +76.0% | +88.8% | +94.8% | +87.0% | +82.6% |
| RSI (14)Momentum oscillator 0–100 | 73.2 | 83.3 | 62.0 | 76.4 | 83.9 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 8.1M | 7.3M | 1.9M | 5.7M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: HUM as "Hold", UNH as "Buy", CVS as "Buy", ELV as "Buy", CNC as "Buy". Consensus price targets imply 18.0% upside for CVS (target: $95) vs -3.7% for CNC (target: $51). For income investors, CVS offers the higher dividend yield at 3.31% vs HUM's 1.49%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $246.00 | $385.43 | $95.20 | $382.38 | $51.00 |
| # AnalystsCovering analysts | 44 | 52 | 41 | 37 | 43 |
| Dividend YieldAnnual dividend ÷ price | +1.5% | +2.4% | +3.3% | +1.9% | — |
| Dividend StreakConsecutive years of raises | 0 | 25 | 0 | 15 | 1 |
| Dividend / ShareAnnual DPS | $3.56 | $8.70 | $2.67 | $6.89 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.5% | +1.7% | 0.0% | +3.3% | +1.8% |
CVS leads in 2 of 6 categories (Total Returns, Risk & Volatility). UNH leads in 1 (Income & Cash Flow). 1 tied.
HUM vs UNH vs CVS vs ELV vs CNC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HUM or UNH or CVS or ELV or CNC a better buy right now?
For growth investors, Centene Corporation (CNC) is the stronger pick with 19.
4% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Elevance Health Inc. (ELV) offers the better valuation at 14. 7x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HUM or UNH or CVS or ELV or CNC?
On trailing P/E, Elevance Health Inc.
(ELV) is the cheapest at 14. 7x versus CVS Health Corporation at 58. 1x. On forward P/E, CVS Health Corporation is actually cheaper at 11. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — HUM or UNH or CVS or ELV or CNC?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +11.
9%, compared to -44. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: UNH returned +217. 0% versus CVS's -2. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HUM or UNH or CVS or ELV or CNC?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus UnitedHealth Group Incorporated's 0. 59β — meaning UNH is approximately 1059% more volatile than CVS relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — HUM or UNH or CVS or ELV or CNC?
By revenue growth (latest reported year), Centene Corporation (CNC) is pulling ahead at 19.
4% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Humana Inc. grew EPS -1. 4% year-over-year, compared to -315. 8% for Centene Corporation. Over a 3-year CAGR, HUM leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HUM or UNH or CVS or ELV or CNC?
Elevance Health Inc.
(ELV) is the more profitable company, earning 2. 8% net margin versus -3. 4% for Centene Corporation — meaning it keeps 2. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -3. 9% for CNC. At the gross margin level — before operating expenses — ELV leads at 25. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HUM or UNH or CVS or ELV or CNC more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 11.
3x forward P/E versus 26. 8x for Humana Inc. — 15. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CVS: 18. 0% to $95. 20.
08Which pays a better dividend — HUM or UNH or CVS or ELV or CNC?
In this comparison, CVS (3.
3% yield), UNH (2. 4% yield), ELV (1. 9% yield), HUM (1. 5% yield) pay a dividend. CNC does not pay a meaningful dividend and should not be held primarily for income.
09Is HUM or UNH or CVS or ELV or CNC better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 3% yield). Both have compounded well over 10 years (CVS: -2. 2%, CNC: +74. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HUM and UNH and CVS and ELV and CNC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HUM is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; ELV is a mid-cap deep-value stock; CNC is a mid-cap high-growth stock. HUM, UNH, CVS, ELV pay a dividend while CNC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.